11 results
The aim of this study is to determine the effects of propranolol on patients* crucial fear-related memories and dental trait anxiety in those undergoing surgical removal of one of their teeth or molars. The hypotheses that are tested are that…
The goal of the present study is to investigate whether the blockade of NA-transmission by beta-antagonist propranolol reduces the common EMDR effects (reduced vividness/emotionality of emotional memories) in order to find out if NA-release (evoked…
The aim of the study is to examine the effect of propranolol on intrusive memories of people suffering from a specific phobia (i.e. dental phobia). It is hypothesized that the administration of propranolol prior to dental treatment:1. would be…
The objective is to study the effect of beta-agonist and beta-antagonist treatment on human bone remodeling.
• To elucidate the role of noradrenaline in the mechanisms involved in human memory consolidation• Evaluate the levels of cortisol and 3-methoxy-4-hydroxyphenylglycol in the various points of a memory consolidation window• Define pharmacological…
To establish the drug drug interaction of paracetamol with propranolol and the effect of this interaction on the pharmacokinetic profile and metabolites of paracetamol.
To study nocturnal FFA rhythm with or without *-blockers in insulin resistant subjects and healthy controls.
To anwer the question: Is the elevation of energy expenditure and mitochondrial uncoupling smaller in obese than in lean subjects after mild cold exposure and what is the role of the sympathetic nervous system?
To evaluate whether acute stress induced by a byngy jump alters the status of the innate immune system
Our aim is to test whether disrupting the process of fear memory reconsolidation is an effective as well as efficient intervention for patients with panic disorder. A secondary aim is to test whether the expected reduction in panic attacks and…
The primary objective is to determine the clinical response of propranolol monotherapy in patients with angiosarcoma. The secondary endpoint is to assess the pathologic response of propranolol monotherapy in patients with angiosarcoma.